Term ends Dec 12, 2026 · Medium confidence
20-year base term ends Dec 12, 2026
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 7,855,291), so the cap could be lower.
Dec 12, 2006
Dec 12, 2026
Jan 14, 2014
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 12, 2006, when application 11/638,677, the earliest non-provisional in its chain, was filed (this one was filed Nov 7, 2011) | Dec 12, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,855,291) | resolves to Dec 12, 2026, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 12, 2026 | Medium confidence |
This family
| US 7,723,345 | In force Dec 2026 | Dec 2026 |
| US 8,063,057 | In force Dec 2026 | Dec 2026 |
| US 8,629,156 | this patent Dec 2026 | Dec 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 20, 2017 Reel 44958, frame 377 | Lexicon Pharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Sep 9, 2020 Reel 53721, frame 37 | Tersera Therapeutics LLC | Newstone Capital Partners, LLC | Security Interest |
| Sep 14, 2020 Reel 53767, frame 445 | Biopharma Credit PLC | Lexicon Pharmaceuticals, Inc. | Release of Security Interest |
| Sep 14, 2020 Reel 53763, frame 754 | Lexicon Pharmaceuticals, Inc. | Tersera Therapeutics LLC | Assignment of Assignor's Interest |
| Sep 30, 2020 Reel 53940, frame 1 | Tersera Therapeutics LLC | Midcap Financial Trust, As Agent | Security Interest |
| Apr 4, 2023 Reel 63215, frame 724 | Tersera Therapeutics LLC | Antares Capital LP, as Agent | Security Interest |
| Apr 4, 2023 Reel 63221, frame 546 | Newstone Capital Partners, LLC | Tersera Therapeutics LLC; JDP Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 Reel 63253, frame 942 | Midcap Financial Trust, As Agent | Tersera Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 reel/frame not recorded | Newstone Capital Partners, LLC | Tersera Therapeutics LLC | Release of Security Interest |
| Apr 4, 2023 reel/frame not recorded | Newstone Capital Partners, LLC | JDP Therapeutics LLC | Release of Security Interest |
| Apr 5, 2023 Reel 63227, frame 852 | Tersera Therapeutics LLC | Newstone Capital Partners, LLC | Security Interest |
| Jan 7, 2025 Reel 69835, frame 704 | Newstone Capital Partners, LLC | Tersera Therapeutics LLC | Release of Intellectual Property Security Agreement Recorded at R/F 63227/0852 |
| Apr 15, 2026 Reel 75420, frame 453 | Midcap Financial Trust | Tersera Therapeutics LLC, | Release of Intellectual Property Security Agreements at R/F 41939/0487, 46591/0544 and 53940/0001 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 7,855,291, ends no earlier than this term, so it caps nothing.